1. Home
  2. LUNG vs MIST Comparison

LUNG vs MIST Comparison

Compare LUNG & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

SELL

Current Price

$1.78

Market Cap

97.1M

Sector

Health Care

ML Signal

SELL

Logo Milestone Pharmaceuticals Inc.

MIST

Milestone Pharmaceuticals Inc.

HOLD

Current Price

$0.77

Market Cap

95.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LUNG
MIST
Founded
1995
2003
Country
United States
Canada
Employees
N/A
38
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
97.1M
95.3M
IPO Year
2020
2019

Fundamental Metrics

Financial Performance
Metric
LUNG
MIST
Price
$1.78
$0.77
Analyst Decision
Buy
Strong Buy
Analyst Count
5
7
Target Price
$3.40
★ $5.86
AVG Volume (30 Days)
258.6K
★ 1.1M
Earning Date
10-27-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 7.64
N/A
EPS
N/A
★ N/A
Revenue
★ $90,497,000.00
N/A
Revenue This Year
$0.06
$147.62
Revenue Next Year
$8.58
$476.43
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 8.01
N/A
52 Week Low
$1.13
$0.71
52 Week High
$2.89
$3.06

Technical Indicators

Market Signals
Indicator
LUNG
MIST
Relative Strength Index (RSI) 40.22 39.07
Support Level $1.68 $0.75
Resistance Level $2.12 $1.42
Average True Range (ATR) 0.10 0.06
MACD -0.01 0.01
Stochastic Oscillator 19.64 37.03

Price Performance

Historical Comparison
LUNG
MIST

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

About MIST Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.

Share on Social Networks: